Manage cutaneous adverse effects induced by diabetes medications or devices by removing the offending agent and choosing appropriate treatment

AbstractNumerous cutaneous adverse effects (CAEs) have been reported with glucose-lowering medications (e.g. insulin, dipeptidyl peptidase  4 inhibitors and sulfonylureas) and medical devices (e.g. continuous subcutaneous insulin infusion and continuous glucose monitoring) used in the management of diabetes. Notable CAEs include angioedema, autoimmune blistering diseases, contact dermatitis, Stevens-Johnson syndrome and worsening bloo d glucose control. While some of CAEs are common and others rare, it is important for healthcare providers to be aware of the potential culprits and their associated CAEs, as well as effective methods to prevent and/or treat such effects.
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research